Mead Johnson Nutritionals Enfamil formula posts third quarter 6% rise to $165 mil..
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS' MEAD JOHNSON NUTRITIONALS SALES RISE 10% TO $443 MIL. in the third quarter, Bristol- Myers Squibb reported Oct. 22. Excluding the effects of foreign exchange, Mead Johnson would have posted an 11% sales gain, BMS noted. Sales of nutritionals were led by Enfamil, the firm's best-selling formula, which had revenues of $165 mil. in the third quarter, an increase of 6% from the year-earlier period.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning